|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Gemfibrozil#Adverse Reactions]] |
| {{Gemfibrozil}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Adverse Reactions==
| |
| In the double-blind controlled phase of the primary prevention component of the Helsinki Heart Study, 2046 patients received LOPID for up to five years. In that study, the following adverse reactions were statistically more frequent in subjects in the LOPID group:
| |
| {|
| |
| |[[File:Gemfibrozil01.png|thumb|800px]]
| |
| |}
| |
| Gallbladder surgery was performed in 0.9% of LOPID and 0.5% of placebo subjects in the primary prevention component, a 64% excess, which is not statistically different from the excess of gallbladder surgery observed in the [[clofibrate]] group compared to the placebo group of the WHO study. Gallbladder surgery was also performed more frequently in the LOPID group compared to the placebo group (1.9% versus 0.3%, p=0.07) in the secondary prevention component. A statistically significant increase in appendectomy in the gemfibrozil group was seen also in the secondary prevention component (6 on gemfibrozil versus 0 on placebo, p=0.014).
| |
| | |
| Nervous system and special senses adverse reactions were more common in the LOPID group. These included [[hypesthesia]], [[paresthesias]], and taste perversion. Other adverse reactions that were more common among LOPID treatment group subjects but where a causal relationship was not established include [[cataracts]], [[peripheral vascular disease]], and [[intracerebral hemorrhage]].
| |
| | |
| From other studies it seems probable that LOPID is causally related to the occurrence of MUSCULOSKELETAL SYMPTOMS (see WARNINGS), and to ABNORMAL LIVER FUNCTION TESTS and HEMATOLOGIC CHANGES (see PRECAUTIONS).
| |
| | |
| Reports of viral and bacterial infections (common cold, cough, [[urinary tract infection]]s) were more common in gemfibrozil treated patients in other controlled clinical trials of 805 patients. Additional adverse reactions that have been reported for gemfibrozil are listed below by system. These are categorized according to whether a causal relationship to treatment with LOPID is probable or not established:
| |
| | |
| {|
| |
| |[[File:Gemfibrozil02-vert.jpg|thumb|800px]]
| |
| |}
| |
| | |
| Additional adverse reactions that have been reported include [[cholecystitis]] and [[cholelithiasis]] (see WARNINGS).<ref>{{Cite web | last = | first = | title = DailyMed: Search | url = http://dailymed.nlm.nih.gov/dailymed/search.cfm?startswith=+Lopid&x=11&y=10 | publisher = | date = | accessdate = 13 February 2014 }}</ref>
| |
| | |
| ==References==
| |
| | |
| {{Reflist|2}}
| |
|
| |
|
| | [[Category: Cardiovascular Drugs]] |
| | [[Category: Drug]] |
| [[Category:Fibrates]] | | [[Category:Fibrates]] |
| [[Category:Phenol ethers]]
| |
| [[Category:Cardiovascular Drug]]
| |
| [[Category:Drug]]
| |